11beta,17,21-三羟基孕甾-4-烯-3,20-二酮 21-甲烷磺酸酯 | 6677-96-9

• 物质功能分类: 化学试剂 - 有机试剂
• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 中文名称: 11beta,17,21-三羟基孕甾-4-烯-3,20-二酮 21-甲烷磺酸酯
• 中文别名: 11beta,17,21-三羟基孕甾-4-烯-3,20-二酮21-甲烷磺酸酯
• 英文名称: Cortisol 21-mesylate
• 英文别名: cortisol-21-methanesulfonate；11β,7α-dihydroxy-21-<(methylsulfonyl)oxy>pregn-4-ene-3,20-dione；11β,17α,21-trihydroxypregn-4-ene-3,20-dione 21-mesylate；11β,17-dihydroxy-21-methanesulfonyloxy-pregn-4-ene-3,20-dione；11β,17,21-trihydroxypregn-4-ene-3,20-dione 21-methanesulfonate；4-pregnene-11-beta,17-alpha,21-triol-3,20-dione-21-methane-sulfonate；11β,17-Dihydroxy-21-methansulfonyloxy-pregn-4-en-3,20-dion；hydrocortisone-21-mesylate；[2-[(8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] methanesulfonate
• CAS: 6677-96-9
• 化学式: C₂₂H₃₂O₇S
• 分子量: 440.558
• InChiKey: AFMXNPUMXZCVGU-CWNVBEKCSA-N

物化性质

• 溶解度：
  可溶于二氯甲烷、乙酸乙酯、甲醇

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  30
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  126
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  11beta,17,21-三羟基孕甾-4-烯-3,20-二酮 21-甲烷磺酸酯 在 氢氧化钾 作用下， 以 乙醇 为溶剂， 生成 4-雄烯-11β-醇-3,17-二酮
  参考文献：
  名称：

  17-Ketosteroids via a base induced cleavage of C-17-dihydroxy acetone side chains

  摘要：

  A new, base-catalyzed cleavage of C21-steroids to give 17-ketosteroids is described. This reaction is specific for those steroids containing the C-17-dihydroxy acetone side chain. In the presence of oxygen, these same reaction conditions readily degrade corticosterone to the 17 beta-carboxylic acid.

  DOI：

  10.1016/s0039-128x(81)90264-6
• 作为产物：
  描述：

  氢化可的松 、 甲基磺酰氯 在 吡啶 作用下， 生成 11beta,17,21-三羟基孕甾-4-烯-3,20-二酮 21-甲烷磺酸酯
  参考文献：
  名称：

  Reduction of some mesyloxy and tosyloxy steroids with sodium iodide and zinc dust

  摘要：

  通过使用碘化钠和锌粉在1,2-二甲氧基乙烷中还原主要和次要类固醇醇的甲磺酸酯和对甲苯磺酸酯，被证明是一种温和而简单的制备方法，用于去除多功能化合物中的羟基。该方法可以成功应用于具有孤立双键、酮基、α-羟基酮、α,α'-二羟基酮或α,β-不饱和酮基团、孤立三级羟基、环氧环或腈基的物质。所有这些功能都不受影响。

  DOI：

  10.1135/cccc19790246

文献信息

• [EN] C20-C21 SUBSTITUTED GLUCOCORTICOID RECEPTOR AGONISTS<br/>[FR] AGONISTES DU RÉCEPTEUR DE GLUCOCORTICOÏDE SUBSTITUÉS EN C20-C21
  申请人：SCHERING CORP

  公开号：WO2009085879A2

  公开（公告）日：2009-07-09

  The present invention provides compounds of Formula (I), and pharmaceutically acceptable salts, solvates, esters, prodrugs, tautomers, or isomers of said compounds), having general structure (I); wherein L, R1, R2, R3, R4, R5, and R6 are selected independently of each other and as defined herein. The present invention also provides compounds (and salts, solvates, esters, prodrugs, tautomers, and isomers) of Formulas II, III, IV, V, and Vl, as defined herein. Also provided are pharmaceutical compositions, methods of preparing, and methods of using such compounds in the treatment and prophylaxis of a wide range of immune, autoimmune, and inflammatory diseases and conditions.

  本发明提供了具有一般结构（I）的化合物，以及该化合物的药用盐、溶剂合物、酯、前药、互变体或异构体（包括L、R1、R2、R3、R4、R5和R6在内独立选择的定义）。本发明还提供了根据本文所定义的化合物（和盐、溶剂合物、酯、前药、互变体和异构体）的II、III、IV、V和VI式化合物。还提供了药物组合物、制备方法以及利用这些化合物在治疗和预防各种免疫、自身免疫和炎症性疾病和症状中的方法。
• Synthesis and Evaluation of Sulfur-Containing Steroids against Methylmercuric Chloride Toxicity
  作者：Larry K. Steinrauf、Brian Cox、Emerson Foster、Amira Sattar、Robert T. Blickenstaff

  DOI：10.1002/jps.2600671228

  日期：1978.12

  Sulfur-containing steroids, analogs, and derivatives were synthesized for evaluation in mice suffering acute toxicity from methylmercuric chloride. Steroids were administered by intraperitoneal injection, by stomach tube feeding, or by absorption through the tail skin. Thiocholesterol and the thiocholanoic acids were effective if given prior to poisoning. The thiosteroids were significantly more effective

  合成了含硫的类固醇，类似物和衍生物，用于在遭受氯化甲基汞急性毒性的小鼠中进行评估。类固醇通过腹膜内注射，胃管进食或通过尾巴皮肤吸收进行给药。如果在中毒前服用硫代胆固醇和硫代胆酸是有效的。在这些条件下，类固醇比青霉素或二巯基己内酯显着更有效。
• [EN] PHARMACEUTICAL COMPOSITIONS AND METHODS<br/>[FR] COMPOSITIONS PHARMACEUTIQUES ET MÉTHODES
  申请人：POP TEST ONCOLOGY LLC

  公开号：WO2017023694A1

  公开（公告）日：2017-02-09

  This invention relates the use of Cortisol blockers (e.g., glucocorticoid receptor [GR] antagonists) for the treating or preventing viral infections, treating or preventing treatment resistant prostate cancer, treating or preventing neoplasia, and treating or preventing infection related to acute or chronic injury or disease.

  本发明涉及使用皮质醇阻断剂（例如，糖皮质激素受体[GR]拮抗剂）用于治疗或预防病毒感染，治疗或预防难治性前列腺癌，治疗或预防肿瘤，以及治疗或预防与急性或慢性损伤或疾病相关的感染。
• Synthesis and use of reagents for improved DNA lipofection and/or slow release prodrug and drug therapies
  申请人：Diamond L. Scott

  公开号：US20050069577A1

  公开（公告）日：2005-03-31

  The invention relates to compositions and methods for a one-step synthetic technique for making cationic steroid or cationic drug molecules for use as delivery vehicles. The invention further relates to methods for using cationic steroid molecules in lipofection or transfection, delivery of drugs, and for treatment of inflammation and other diseases and disorders. The invention also relates to cationic steroid prodrugs and cationic prodrugs and to methods of modifying drugs.

  本发明涉及一种用于制备阳离子类固醇或阳离子类药物分子的一步合成技术的组合物和方法，用作传递载体。该发明还涉及使用阳离子类固醇分子进行脂质体转染或转染、药物传递以及治疗炎症和其他疾病和障碍的方法。该发明还涉及阳离子类固醇前药和阳离子前药以及修改药物的方法。
• Synthesis and Use of Cationic Steroids for Anti-Inflammatory Drug Therapy
  申请人：Diamond Scott L.

  公开号：US20090124591A1

  公开（公告）日：2009-05-14

  The invention relates to compositions and methods for a one-step synthetic technique for making cationic steroid pharmaceutical compositions for use in treating inflammation and other diseases and disorders.

  本发明涉及一种用于制备阳离子类固醇药物组合物的一步合成技术及其用于治疗炎症和其他疾病和障碍的方法。